ArticleFood science & nutrition2025
Effect and Mechanisms of Yiqi Jianpi Xiaoyu Prescription on Kidney Fibrosis on the Basis of Metabolomics and Experimental Validation.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect and Mechanisms of Yiqi Jianpi Xiaoyu Prescription on Kidney Fibrosis on the Basis of Metabolomics and Experimental Validation.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Yiqi Jianpi Xiaoyu prescription (YQJPXY) exhibits ameliorative effects on kidney fibrosis, but the underlying mechanism related to metabolism remains insufficient. We aimed to explore the antifibrotic effects of YQJPXY on kidney fibrosis and its underlying mechanism using serum metabolomics, biochemical analyses, and experimental analyses. We established a unilateral ureteral obstruction (UUO) kidney fibrosis mouse model, dividing mice into sham, model, YQJPXY-treated (7.28, 14.56, 29.12 g/kg/day), and Losartan groups. Renal function, histopathology, and fibrosis markers (FN, Col IV, and α-SMA) were analyzed. Serum metabolomic (UHPLC-Q-TOF/MS) identified key metabolites. TEM, qRT-PCR, WB, ELISA, and immunohistochemical validation confirmed the Adenosine mechanism in promoting autophagy through the A2BR/cAMP/AMPK pathway in the process of YQJPXY against kidney fibrosis. TGF-β-induced HK-2 cell fibrosis with autophagy inhibitor (CQ), A2BR inhibitor (PSB1115), and AMPK inhibitor (Dorsomorphin) explored the mechanism. YQJPXY improved kidney function and fibrosis. Metabolomics identified five important metabolites in kidney fibrosis: Adenosine monophosphate, Adenosine, Adenine, Inosine, and Hypoxanthine. Among these, Adenosine, which attenuated fibrosis via A2BR/cAMP/AMPK-mediated autophagy, was inhibited by CQ, PSB1115, and Dorsomorphin. YQJPXY's antifibrotic mechanism involves adenosine-activated A2BR/cAMP/AMPK autophagy pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.